Lisata Therapeutics Inc.

There's a company called North, an immunology company that will have, uh, $180 million in new funding via reverse merger and pipe, one of those deals.

And in a slightly more traditional merger, a company called Lisata is acquiring someone else called Mireia.

It will retain the Lisata name, but they'll have $225 million in fresh capital that will go toward development of Mireia's products for hypertriglyceridemia, there's that word, and, uh, acromegaly.

So that's almost like a reverse merger.

Not quite.

In today's Pharmaceutical Executive Daily, FDA approves Ultragenyx's Feiyuvi as the first treatment for Sanfilippo syndrome type A in pediatric patients ages 2 to 5.

An M&A roundup covers Lisata Therapeutics' acquisition of Maria Therapeutics and Mabex Science's biosimilar collaboration with Sandoz.

And Pharmaceutical Executive speaks with Joe Cunningham on why most favored nation pricing deals alone aren't enough to lower drug costs.

FDA approves Ultragenyx's FiUV, Rebusuflagene et Asparvovec-Hoff, as the first treatment for mucopolysaccharidosis type 3a or Sanfilippo syndrome type A in pediatric patients ages 2 to 5.